MSI status has been negatively associated with SIGLEC9 expression in head–neck squamous cell carcinoma (HNSC), glioma, lung cancer, pancreatic adenocarcinoma (PAAD), SKCM, and tenosynovial giant cell tumors (TGCTs), but positively in CRC. Here, SIGLEC9 is linked to glioma.